These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 2855296)
21. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. Ciofu O APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154 [TBL] [Abstract][Full Text] [Related]
22. Comparison of cefpiramide (HR-810) and four anti-pseudomonal beta-lactam agents against pseudomonas isolates from children with cystic fibrosis. Aronoff SC; Klinger JD J Antimicrob Chemother; 1985 May; 15(5):545-9. PubMed ID: 3924879 [TBL] [Abstract][Full Text] [Related]
23. Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams. Lerner SA; Quinn JP Chemioterapia; 1985 Feb; 4(1):95-101. PubMed ID: 3921267 [TBL] [Abstract][Full Text] [Related]
24. Lack of efflux mechanism in a clinical isolate of Pseudomonas aeruginosa highly resistant to beta-lactams and imipenem. Kadry AA Folia Microbiol (Praha); 2003; 48(4):529-33. PubMed ID: 14533486 [TBL] [Abstract][Full Text] [Related]
25. Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant. Angus BL; Carey AM; Caron DA; Kropinski AM; Hancock RE Antimicrob Agents Chemother; 1982 Feb; 21(2):299-309. PubMed ID: 6803666 [TBL] [Abstract][Full Text] [Related]
26. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848 [TBL] [Abstract][Full Text] [Related]
27. Carbapenem resistance in cystic fibrosis strains of Pseudomonas aeruginosa as a result of amino acid substitutions in porin OprD. Richardot C; Plésiat P; Fournier D; Monlezun L; Broutin I; Llanes C Int J Antimicrob Agents; 2015 May; 45(5):529-32. PubMed ID: 25735764 [TBL] [Abstract][Full Text] [Related]
28. [Studies on the outer membrane permeability of bacteria]. Nakae T Nihon Saikingaku Zasshi; 1990 Jul; 45(4):777-84. PubMed ID: 2122042 [No Abstract] [Full Text] [Related]
29. Penicillin-binding protein 3 is a common adaptive target among Pseudomonas aeruginosa isolates from adult cystic fibrosis patients treated with β-lactams. Clark ST; Sinha U; Zhang Y; Wang PW; Donaldson SL; Coburn B; Waters VJ; Yau YCW; Tullis DE; Guttman DS; Hwang DM Int J Antimicrob Agents; 2019 May; 53(5):620-628. PubMed ID: 30664925 [TBL] [Abstract][Full Text] [Related]
30. ISPa46, a novel insertion sequence in the oprD porin gene of an imipenem-resistant Pseudomonas aeruginosa isolate from a cystic fibrosis patient in Marseille, France. Diene SM; L'homme T; Bellulo S; Stremler N; Dubus JC; Mely L; Leroy S; Degand N; Rolain JM Int J Antimicrob Agents; 2013 Sep; 42(3):268-71. PubMed ID: 23880169 [TBL] [Abstract][Full Text] [Related]
31. Permeability to carbapenems of Proteus mirabilis mutants selected for resistance to imipenem or other beta-lactams. Villar HE; Danel F; Livermore DM J Antimicrob Chemother; 1997 Sep; 40(3):365-70. PubMed ID: 9338488 [TBL] [Abstract][Full Text] [Related]
32. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients. Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560 [TBL] [Abstract][Full Text] [Related]
33. Involvement of a 43-kilodalton outer membrane protein in beta-lactam resistance of Shigella dysenteriae. Kar AK; Ghosh AS; Chauhan K; Ahamed J; Basu J; Chakrabarti P; Kundu M Antimicrob Agents Chemother; 1997 Oct; 41(10):2302-4. PubMed ID: 9333070 [TBL] [Abstract][Full Text] [Related]
34. Lack of additive effect between mechanisms of resistance to carbapenems and other beta-lactam agents in Pseudomonas aeruginosa. Dib C; Trias J; Jarlier V Eur J Clin Microbiol Infect Dis; 1995 Nov; 14(11):979-86. PubMed ID: 8654449 [TBL] [Abstract][Full Text] [Related]
35. Association of resistance to trimethoprim/sulphamethoxazole, chloramphenicol and quinolones with changes in major outer membrane proteins and lipopolysaccharide in Burkholderia cepacia. Rajyaguru JM; Muszynski MJ J Antimicrob Chemother; 1997 Dec; 40(6):803-9. PubMed ID: 9462431 [TBL] [Abstract][Full Text] [Related]
36. Amelioration of the Fitness Costs of Antibiotic Resistance Due To Reduced Outer Membrane Permeability by Upregulation of Alternative Porins. Knopp M; Andersson DI Mol Biol Evol; 2015 Dec; 32(12):3252-63. PubMed ID: 26358402 [TBL] [Abstract][Full Text] [Related]
37. Prevalence of outer membrane porin alteration in beta-lactam-antibiotic-resistant Enterobacter aerogenes. Charrel RN; Pagès JM; De Micco P; Mallea M Antimicrob Agents Chemother; 1996 Dec; 40(12):2854-8. PubMed ID: 9124854 [TBL] [Abstract][Full Text] [Related]
38. Evolution of extended-spectrum beta-lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Rasheed JK; Jay C; Metchock B; Berkowitz F; Weigel L; Crellin J; Steward C; Hill B; Medeiros AA; Tenover FC Antimicrob Agents Chemother; 1997 Mar; 41(3):647-53. PubMed ID: 9056008 [TBL] [Abstract][Full Text] [Related]
39. Lipopolysaccharide alterations responsible for combined quinolone and beta-lactam resistance in Pseudomonas aeruginosa. Leying HJ; Büscher KH; Cullmann W; Then RL Chemotherapy; 1992; 38(2):82-91. PubMed ID: 1591950 [TBL] [Abstract][Full Text] [Related]
40. Beta-lactamases and outer membrane investigations in beta-lactam-resistant Comamonas acidovorans strains. Ravaoarinoro M; Therrien C Int J Antimicrob Agents; 1999 Jun; 12(1):27-31. PubMed ID: 10389644 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]